C2CD5: A Protein with Potential as A Drug Target and Biomarker

Target Name: C2CD5

NCBI ID: G9847

C2CD5

C2CD5: A Protein with Potential as A Drug Target and Biomarker

C2CD5 is a protein that is expressed in various tissues of the human body, including the brain, heart, and gastrointestinal tract. It is a member of the T-cell receptor family and is involved in the immune response. Researchers have identified C2CD5 as a potential drug target and have used various techniques to study its biology and potential therapeutic applications.

One of the main studies that has investigated C2CD5 is the C2CD5_HUMAN trial. This clinical trial was designed to evaluate the safety and efficacy of the drug optimaVACIS-101, which is a monoclonal antibody targeting C2CD5, in patients with relapsed or refractory diffuse large B-cell lymphoma. The trial showed that treatment with optimaVACIS-101 led to a significant improvement in the overall response rate and a higher proportion of responders in comparison to historical controls.

Another study that has explored the potential of C2CD5 as a drug target is the use of C2CD5-targeted antibodies. Researchers have developed a monoclonal antibody that targets C2CD5 and used it to treat patients with various diseases, including cancer. The studies have shown that these antibodies are able to selectively bind to C2CD5 and can effectively inhibit its activity, leading to potential therapeutic benefits.

In addition to its potential as a drug target, C2CD5 has also been investigated for its potential as a biomarker. The team behind the C2CD5_HUMAN trial has used C2CD5 as a biomarker to predict the response to optimaVACIS-101 in patients with relapsed or refractory diffuse large B-cell lymphoma. The results of this study have shown that C2CD5 levels can be used as a predictor of treatment response in patients with lymphoma, providing insight into the underlying biology of the disease and the potential for personalized medicine.

Overall, the research into C2CD5 has shown that it has the potential to be a drug target and a biomarker in various diseases. Further studies are needed to fully understand its biology and develop effective therapies based on its properties.

Protein Name: C2 Calcium Dependent Domain Containing 5

Functions: Required for insulin-stimulated glucose transport and glucose transporter SLC2A4/GLUT4 translocation from intracellular glucose storage vesicle (GSV) to the plasma membrane (PM) in adipocytes. Binds phospholipid membranes in a calcium-dependent manner and is necessary for the optimal membrane fusion between SLC2A4/GLUT4 GSV and the PM

The "C2CD5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C2CD5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets